Industry
Biotechnology
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.
Loading...
Open
40.00
Mkt cap
1.1B
Volume
9.8K
High
43.00
P/E Ratio
-22.73
52-wk high
43.00
Low
40.00
Div yield
N/A
52-wk low
15.25
Portfolio Pulse from Avi Kapoor
May 28, 2024 | 5:24 pm
Portfolio Pulse from Benzinga Insights
May 28, 2024 | 4:31 pm
Portfolio Pulse from Vandana Singh
May 28, 2024 | 4:03 pm
Portfolio Pulse from Avi Kapoor
May 28, 2024 | 4:00 pm
Portfolio Pulse from Benzinga Newsdesk
May 28, 2024 | 3:00 pm
Portfolio Pulse from Avi Kapoor
May 28, 2024 | 2:31 pm
Portfolio Pulse from Benzinga Insights
May 28, 2024 | 12:07 pm
Portfolio Pulse from Avi Kapoor
May 28, 2024 | 12:04 pm
Portfolio Pulse from Benzinga Newsdesk
May 28, 2024 | 11:29 am
Portfolio Pulse from Benzinga Newsdesk
May 28, 2024 | 8:38 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.